WHO Diagnostic Criteria for Polycythemia Vera (2016)
ورودیهای بالینی بیمار
حداقل ۵ — حداکثر ۲۵ • واحد: g/dL
حداقل ۱۰ — حداکثر ۸۰ • واحد: %
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
The WHO Diagnostic Criteria for Polycythemia Vera (2016) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include gender. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
World Health Organization 2016 diagnostic criteria for polycythemia vera. Requires 3 major criteria OR 2 major criteria + 1 minor criterion for diagnosis. Designed to detect masked polycythemia vera cases missed by previous 2008 criteria.
Clinical Indication
The WHO Diagnostic Criteria for Polycythemia Vera (2016) is indicated for bedside clinical practice to support World Health Organization 2016 diagnostic criteria for polycythemia vera. Requires 3 major criteria OR 2 major criteria + 1 minor criterion for diagnosis. Designed to detect masked polycythemia vera cases missed by previous 2008 criteria.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
Diagnosis requires meeting 3 major criteria OR 2 major criteria + 1 minor criterion. Major criteria: (1) Hemoglobin >16.5 g/dL (men) or >16.0 g/dL (women) OR Hematocrit >49% (men) or >48% (women) OR elevated red cell mass >25% above normal; (2) Bone marrow hypercellularity with trilineage growth; (3) JAK2V617F or JAK2 exon 12 mutation. Minor criterion: Subnormal serum erythropoietin level.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| gender | string | Yes | Patient gender (affects hemoglobin and hematocrit thresholds) |
| hemoglobin | float | Yes | Hemoglobin level in g/dL(g/dL) |
| hematocrit | float | Yes | Hematocrit percentage(%) |
| red_cell_mass_elevated | string | Yes | Red cell mass >25% above mean normal predicted value (alternative to Hgb/Hct criteria) |
| bone_marrow_hypercellular | string | Yes | Bone marrow biopsy showing hypercellularity for age with trilineage growth including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes |
| jak2_mutation | string | Yes | Presence of JAK2V617F or JAK2 exon 12 mutation |
| erythropoietin_level | string | Yes | Serum erythropoietin (EPO) level status |
Evidence-Based References (EBM)
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi: 10.1182/blood-2016-03-643544DOI: 10.1182/blood-2016-03-643544
- Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi: 10.1038/s41408-018-0054-yDOI: 10.1038/s41408-018-0054-y
- Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599-1613. doi: 10.1002/ajh.26008DOI: 10.1002/ajh.26008
- Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786-793. doi: 10.1111/bjh.13884DOI: 10.1111/bjh.13884
Related calculators
- International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF)
- DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis
- GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis
- Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+)
- Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM)